Loading stock data…
Sana Biotechnology (SANA)
$3.18-0.03 (-0.93%)
Market ClosedLast close Jul 24
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sana Biotechnology, Inc. in the Healthcare sector is trading at $3.18 with a market capitalization of $788M. Wall Street consensus targets $8.57 (7 analysts), implying a +169.5% move over the next 12 months. The stock is currently near its 52-week low of $2.61, remaining 17.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +169.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.61M↑ | -$61.20M↓ | -$43.52M↑ | -$50.36M↑ | -$50.63M |
| Net Income | -$47.21M↑ | -$58.83M↓ | -$42.15M↑ | -$93.80M↓ | -$49.39M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$787.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-202.94%
Volume
Today's trading volume
2.27M
Recent News
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM
Sana Biotechnology (NasdaqGS:SANA) reported long term follow up data from an investigator sponsored study of its HIP modified islet cell therapy for type 1 diabetes. Results published in The New England Journal of Medicine highlighted safety and durable islet cell function over 14 months without the use of immunosuppressive drugs. The transplanted cells were observed to survive, evade immune rejection, and maintain glucose regulating activity through the follow up period. Sana Biotechnology...
Sana (SANA) Upgraded to Buy: Here's What You Should Know
Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?
Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.View on euronews
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the development of SC451, an investigational cell replacement therapy for type 1 diabetes. SC451 uses Sana Biotech’s proprietary hypoimmune technology to engineer pancreatic islet cells that […]